Technical Analysis for OVID - Ovid Therapeutics Inc.

Grade Last Price % Change Price Change
grade F 1.85 -28.02% -0.72
OVID closed down 28.02 percent on Wednesday, February 20, 2019, on 21.96 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
0 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical OVID trend table...

Date Alert Name Type % Chg
Feb 20 New 52 Week Closing Low Bearish 0.00%
Feb 20 Gilligan's Island Buy Setup Bullish Swing Setup 0.00%
Feb 20 Volume Surge Other 0.00%
Feb 20 Doji - Bullish? Reversal 0.00%
Feb 20 New 52 Week Low Weakness 0.00%
Feb 20 Wide Bands Range Expansion 0.00%
Feb 20 Below Lower BB Weakness 0.00%
Feb 20 Gapped Down Weakness 0.00%
Feb 20 Oversold Stochastic Weakness 0.00%
Feb 19 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -28.02%

Older signals for OVID ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Analyze My Stocks!
Configure default chart indicators
Basic chart:

Profile
Ovid Therapeutics Inc. (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist. Ovid is developing OV101 for use in both Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and relieve several of the symptoms of these disorders. Ovid has initiated the Phase II STARS trial of OV101 in adults with Angelman syndrome and a Phase I trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.
Biopharmaceutical Organ Systems Disorders Neurological Disorders Epilepsy Genodermatoses Anticonvulsants Sedatives Fragile X Syndrome Syndromes
Is OVID a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Feb 20 Why A Secondary Offering Is Often Negative For Stocks
Feb 20 Mid-Afternoon Market Update: Crude Oil Up 1.5%; Kandi Technologies Shares Spike Higher
Feb 20 54 Stocks Moving In Wednesday's Mid-Day Session
Feb 20 Mid-Day Market Update: LeMaitre Vascular Surges Following Strong Q4 Results; Sienna Biopharmaceuticals Shares Slide
Feb 20 Midday movers and shakers
Feb 20 LeMaitre Vascular leads healthcare gainers; CHF Solutions and Intercept Pharmaceuticals among losers
Feb 20 Ovid Therapeutics Announces Pricing of $30 Million of Securities in Concurrent Public Offerings of Common and Preferred Stock
Feb 20 The Daily Biotech Pulse: Teva Settles With FTC, Setback For Merck In Liver Cancer Trial, Sienna Biopharma Offering
Feb 19 Ovid down 22% after hours on equity offering
Feb 19 Ovid Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock
See more OVID news...
Indicators
Indicator Value
52 Week High 11.45
52 Week Low 1.72
Average Volume 141,373
200-Day Moving Average 5.9985
50-Day Moving Average 2.9222
20-Day Moving Average 2.7795
10-Day Moving Average 2.472
Average True Range 0.3027
ADX 26.54
+DI 13.7521
-DI 33.2184
Chandelier Exit (Long, 3 ATRs ) 2.6819
Chandelier Exit (Short, 3 ATRs ) 2.6281
Upper Bollinger Band 3.5521
Lower Bollinger Band 2.0069
Percent B (%b) -0.1
BandWidth 55.592733
MACD Line -0.25
MACD Signal Line -0.1888
MACD Histogram -0.0612
Fundamentals Value
Market Cap 45.51 Million
Num Shares 24.6 Million
EPS -4.85
Price-to-Earnings (P/E) Ratio -0.38
Price-to-Sales 0.00
Price-to-Book 1.52
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.12
Resistance 3 (R3) 2.11 2.00 2.08
Resistance 2 (R2) 2.00 1.93 2.01 2.06
Resistance 1 (R1) 1.93 1.89 1.94 1.94 2.04
Pivot Point 1.82 1.82 1.83 1.83 1.82
Support 1 (S1) 1.75 1.75 1.76 1.76 1.66
Support 2 (S2) 1.64 1.71 1.65 1.64
Support 3 (S3) 1.57 1.64 1.63
Support 4 (S4) 1.58